FOS and hepatocellular carcinoma: Next, the MDA-MB-231 and HCC-1937 groups were selected for c-FOS inhibition, and after the addition of the c-FOS inhibitor T5224, the expression of c-FOS in neutrophils significantly decreased, along with a positive correlation with PAD4 (Fig. 4B, Supplementary Fig. S1G, H).